These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17324820)

  • 1. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus.
    Pfütze M; Niedermeier A; Hertl M; Eming R
    Eur J Dermatol; 2007; 17(1):4-11. PubMed ID: 17324820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Oral Disease Severity Score validated for use in oral pemphigus vulgaris.
    Ormond M; McParland H; Donaldson ANA; Andiappan M; Cook RJ; Escudier M; Hullah E; Higham J; McMillan R; Taylor J; Shirlaw PJ; Challacombe SJ; Setterfield JF
    Br J Dermatol; 2018 Oct; 179(4):872-881. PubMed ID: 29297927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus.
    Boulard C; Duvert Lehembre S; Picard-Dahan C; Kern JS; Zambruno G; Feliciani C; Marinovic B; Vabres P; Borradori L; Prost-Squarcioni C; Labeille B; Richard MA; Ingen-Housz-Oro S; Houivet E; Werth VP; Murrell DF; Hertl M; Benichou J; Joly P;
    Br J Dermatol; 2016 Jul; 175(1):142-9. PubMed ID: 26800395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies.
    Mohebi F; Tavakolpour S; Teimourpour A; Toosi R; Mahmoudi H; Balighi K; Ghandi N; Ghiasi M; Nourmohammadpour P; Lajevardi V; Abedini R; Azizpour A; Nasimi M; Daneshpazhooh M
    BMC Dermatol; 2020 Oct; 20(1):13. PubMed ID: 33129291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objective scoring systems for disease activity in autoimmune bullous disease.
    Sebaratnam DF; Murrell DF
    Dermatol Clin; 2011 Jul; 29(3):515-20, xi. PubMed ID: 21605820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ODSS vs. ABSIS and PDAI oral parts in pemphigus vulgaris: inter-rater reliability and testing times.
    Shamabadi A; Yazdinezhad S; Sadeghi Y; Moradi AR; Yazdchi A; Teymourpour A; Faramarzi A; Seirafi R; Balighi K; Mahmoudi H; Daneshpazhooh M
    Oral Dis; 2023 Oct; 29(7):2696-2704. PubMed ID: 35852132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of an Oral Disease Severity Score (ODSS) tool for use in oral mucous membrane pemphigoid.
    Ormond M; McParland H; Thakrar P; Donaldson ANA; Andiappan M; Cook RJ; Escudier ME; Higham J; Hullah E; McMillan R; Taylor J; Shirlaw PJ; Challacombe SJ; Setterfield JF
    Br J Dermatol; 2020 Jul; 183(1):78-85. PubMed ID: 31571192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability and convergent validity of two outcome instruments for pemphigus.
    Rosenbach M; Murrell DF; Bystryn JC; Dulay S; Dick S; Fakharzadeh S; Hall R; Korman NJ; Lin J; Okawa J; Pandya AG; Payne AS; Rose M; Rubenstein D; Woodley D; Vittorio C; Werth BB; Williams EA; Taylor L; Troxel AB; Werth VP
    J Invest Dermatol; 2009 Oct; 129(10):2404-10. PubMed ID: 19357707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Ear, Nose, and Throat Involvement in Pemphigus Vulgaris in Comparison with Pemphigus Severity Scoring Systems: A Cross-sectional Study.
    Bilgic-Teme A; Cem Temel I; Bostancı-Toptas A; Turhan M; Bozkurt S; Uzun S
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):283-288. PubMed ID: 30665476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.
    Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the skin: disease parameters in pemphigus.
    Viti G; Forcella C; Feliciani C; Murrell DF
    Ital J Dermatol Venerol; 2021 Apr; 156(2):147-150. PubMed ID: 33960750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemphigus oral lesions area index (POLAI): A new scoring scale for assessing oral pemphigus vulgaris.
    Wang F; Zhang X; Yao Y; Wang J; Shi Y; Liu T; Xu H; Zhou Y; Dan H; Zeng X
    Oral Dis; 2024 Jun; ():. PubMed ID: 38937974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus.
    Krain RL; Kushner CJ; Tarazi M; Gaffney RG; Yeguez AC; Zamalin DE; Pearson DR; Feng R; Payne AS; Werth VP
    Front Immunol; 2019; 10():2571. PubMed ID: 31781098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oesophageal involvement during attacks in pemphigus vulgaris patients.
    Calka O; Akdeniz N; Tuncer I; Metin A; Cesur RS
    Clin Exp Dermatol; 2006 Jul; 31(4):515-9. PubMed ID: 16716152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in severe pemphigus.
    Schmidt E; Goebeler M; Zillikens D
    Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use?
    Wijayanti A; Zhao CY; Boettiger D; Chiang YZ; Ishii N; Hashimoto T; Murrell DF
    Acta Derm Venereol; 2017 Jan; 97(1):24-31. PubMed ID: 27244117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition from pemphigus foliaceus to bullous pemphigoid: intermolecular B-cell epitope spreading without IgG subclass shifting.
    Recke A; Rose C; Schmidt E; Bröcker EB; Zillikens D; Sitaru C
    J Am Acad Dermatol; 2009 Aug; 61(2):333-6. PubMed ID: 19615544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grading criteria for disease severity by pemphigus disease area index.
    Shimizu T; Takebayashi T; Sato Y; Niizeki H; Aoyama Y; Kitajima Y; Iwatsuki K; Hashimoto T; Yamagami J; Werth VP; Amagai M; Tanikawa A
    J Dermatol; 2014 Nov; 41(11):969-73. PubMed ID: 25346300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severity score indexes for blistering diseases.
    Daniel BS; Hertl M; Werth VP; Eming R; Murrell DF
    Clin Dermatol; 2012; 30(1):108-13. PubMed ID: 22137234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools.
    Paradisi A; Sampogna F; Di Pietro C; Cianchini G; Didona B; Ferri R; Abeni D; Tabolli S
    J Am Acad Dermatol; 2009 Feb; 60(2):261-9. PubMed ID: 19004524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.